Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.

摘要: // Mary Glorieux 1 , Ruveyda Dok and Sandra Nuyts 1, 2 KU Leuven, University of Department Oncology, Laboratory Experimental Radiotherapy, 3000 Belgium Radiation Leuven Cancer Institute, UZ Correspondence to: Nuyts, email: sandra.nuyts@uzleuven.be Keywords: HNSCC, DNA targeted agents, radiation sensitization, biomarkers Received: June 13, 2017      Accepted: August 27, Published: September 16, 2017 ABSTRACT Head neck squamous cell carcinoma is the sixth most common cancer worldwide despite advances in treatment over last years, there still a relapse rate 50%. New therapeutic agents are awaited to increase survival patients. repair combination with standard damaging therapies recent evolution treatment. These focus on damage pathways cells, which often involved resistance. Interesting targets overcome these defense mechanisms are: PARP, DNA-PK, PI3K, ATM, ATR, CHK1/2, WEE1 inhibitors. The application head showed promising preclinical results translated multiple ongoing clinical trials, although no FDA approval has emerged yet. Biomarkers necessary select patients that can benefit from this treatment, adequate limited validation needed predict response.